PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

NCT03269136 PHASE1 COMPLETED Results posted

To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Details

Lead sponsor	Pfizer
Phase	PHASE1
Status	COMPLETED
Enrolment	101
Start date	Wed Nov 29 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jan 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Multiple Myeloma

Interventions

• PF-06863135 monotherapy IV or SC
• PF-06863135 + dexamethasone
• PF-06863135 + lenalidomide
• PF-06863135 + pomalidomide

Countries

Canada, United States